Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enerisant H3 Receptor Occupancy Study
NCT04631276Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Dec 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Enerisant in narcolepsy (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: H3 receptor occupancy at 2 hours, Changes in the H3 receptor occupancy at 26 hours and 1 more. Started Dec 2014; status: completed.
02
Drugs
Enerisant
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT04631276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631276.